Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction Heart Failure Society of America Guidelines Committee

Journal of Cardiac Failure

Volumn 18, Issue 4, 2012, Pages 265-281

  Butler, Javed ^a   Ezekowitz, Justin A ^b   Collins, Sean P ^c   Givertz, Michael M ^d   Teerlink, John R ^e   Walsh, Mary N ^e   Albert, Nancy M ^f   Westlake Canary, Cheryl A ^g   Carson, Peter E ^h   Colvin Adams, Monica ⁱ   Fang, James C ^j   Hernandez, Adrian F ^k   Hershberger, Ray E ^l   Katz, Stuart D ^m   Rogers, Joseph G ^k   Spertus, John A ⁿ   Stevenson, William G ^d   Sweitzer, Nancy K ^o   Wilson Tang, W H ^f   Stough, Wendy Gattis ^p   Starling, Randall C ^f   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c VANDERBILT UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g AZUSA PACIFIC UNIVERSITY   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^m NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^o UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^p CAMPBELL UNIVERSITY   (United States)

more..

Author keywords

Aldosterone antagonists; eplerenone; heart failure; spironolactone

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CANRENOIC ACID; CANRENONE; CORTICOTROPIN; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; ERYTHROMYCIN; HYDRALAZINE; ISOSORBIDE DINITRATE; KETOCONAZOLE; MINERALOCORTICOID RECEPTOR; POTASSIUM; SPIRONOLACTONE;

ADD ON THERAPY; ADRENAL CORTEX; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; CORTICOTROPIN BLOOD LEVEL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE SEVERITY; DOWN REGULATION; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAPEFRUIT JUICE; GYNECOMASTIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HOSPITALIZATION; HUMAN; HYPERKALEMIA; IMPOTENCE; KIDNEY DISTAL TUBULE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MEDICAL SOCIETY; MENSTRUAL IRREGULARITY; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT EDUCATION; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALT INTAKE; SODIUM ABSORPTION; TREATMENT DURATION;

EID: 84859176250     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2012.02.005     Document Type: Article

References (95)

1. J. Lindenfeld, N.M. Albert, J.P. Boehmer, S.P. Collins, J.A. Ezekowitz, and M.M. Givertz HFSA 2010 comprehensive heart failure practice guideline J Card Fail 16 2010 e1 e194
2. R.S. McKelvie, S. Yusuf, D. Pericak, A. Avezum, R.J. Burns, and J. Probstfield Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study nvestigators Circulation 100 1999 1056 1064
3. K. Swedberg, P. Eneroth, J. Kjekshus, and L. Wilhelmsen Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group Circulation 82 1990 1730 1736
4. K.T. Weber Aldosterone in congestive heart failure N Engl J Med 345 2001 1689 1697
5. G. Guder, J. Bauersachs, S. Frantz, D. Weismann, B. Allolio, and G. Ertl Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure Circulation 115 2007 1754 1761
6. J.N. Cohn, I.S. Anand, R. Latini, S. Masson, Y.T. Chiang, and R. Glazer Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial Circulation 108 2003 1306 1309
7. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, and A. Perez The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
8. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, and B. Roniker Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
9. K. Dickstein, A. Cohen-Solal, G. Filippatos, J.J. McMurray, P. Ponikowski, and P.A. Poole-Wilson ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2008 2388 2442
10. S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, and T.G. Ganiats 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 2009 e1 e90
11. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, and H. Shi Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
12. J.A. Luetscher Jr., and B.B. Johnson Observations on the sodium-retaining corticoid (aldosterone) in the urine of children and adults in relation to sodium balance and edema J Clin Invest 33 1954 1441 1446
13. J.O. Davis, M.M. Pechet, W.C. Ball Jr., and M.J. Goodkind Increased aldosterone secretion in dogs with right-sided congestive heart failure and in dogs with thoracic inferior vena cava constriction J Clin Invest 36 1957 689 694
14. R.S. McKelvie, S. Yusuf, D. Pericak, A. Avezum, R.J. Burns, and J. Probstfield Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators Circulation 100 1999 1056 1064
15. K. Swedberg, P. Eneroth, J. Kjekshus, and S. Snapinn Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group Am J Cardiol 66 1990 40D 44D
16. G. Guder, J. Bauersachs, S. Frantz, D. Weismann, B. Allolio, and G. Ertl Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure Circulation 115 2007 1754 1761
17. M. Jessup Aldosterone blockade and heart failure N Engl J Med 348 2003 1380 1382
18. K.T. Weber Aldosterone in congestive heart failure N Engl J Med 345 2001 1689 1697
19. W. Qin, A.E. Rudolph, B.R. Bond, R. Rocha, E.A. Blomme, and J.J. Goellner Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure Circ Res 93 2003 69 76
20. L. Del Vecchio, M. Procaccio, S. Vigano, and D. Cusi Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade Nat Clin Pract Nephrol 3 2007 42 49
21. G.A. Deuchar, D. McLean, P.W. Hadoke, D.G. Brownstein, D.J. Webb, and J.J. Mullins 11beta-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice Endocrinology 152 2011 236 246
22. J.E. Macdonald, N. Kennedy, and A.D. Struthers Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment Heart 90 2004 765 770
23. R.J. MacFadyen, C.S. Barr, and A.D. Struthers Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients Cardiovasc Res 35 1997 30 34
24. R. Rocha, A.E. Rudolph, G.E. Frierdich, D.A. Nachowiak, B.K. Kekec, and E.A. Blomme Aldosterone induces a vascular inflammatory phenotype in the rat heart Am J Physiol Heart Circ Physiol 283 2002 H1802 H1810
25. M.L. Gumz, L.R. Stow, I.J. Lynch, M.M. Greenlee, A. Rudin, and B.D. Cain The circadian clock protein Period 1 regulates expression of the renal epithelial sodium channel in mice J Clin Invest 119 2009 2423 2434
26. S. Huang, A. Zhang, G. Ding, and R. Chen Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation Am J Physiol Renal Physiol 296 2009 F1323 F1333
27. S.H. Lee, T.H. Yoo, B.Y. Nam, D.K. Kim, J.J. Li, and D.S. Jung Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions Am J Physiol Renal Physiol 297 2009 F1381 F1390
28. C. Ronco, M. Haapio, A.A. House, N. Anavekar, and R. Bellomo Cardiorenal syndrome J Am Coll Cardiol 52 2008 1527 1539
29. L.I. Rose, R.H. Underwood, S.R. Newmark, E.S. Kisch, and G.H. Williams Pathophysiology of spironolactone-induced gynecomastia Ann Intern Med 87 1977 398 403
30. G.M. de, U. Joss, H.P. Ramjoue, S.E. Whitebread, H. Haenni, and L. Schenkel Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro J Pharmacol Exp Ther 240 1987 650 656
31. A. Struthers, H. Krum, and G.H. Williams A comparison of the aldosterone-blocking agents eplerenone and spironolactone Clin Cardiol 31 2008 153 158
32. M. Yamaji, T. Tsutamoto, C. Kawahara, K. Nishiyama, T. Yamamoto, and M. Fujii Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure Am Heart J 160 2010 915 921
33. P. Gardiner, K. Schrode, D. Quinlan, B.K. Martin, D.R. Boreham, and M.S. Rogers Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites J Clin Pharmacol 29 1989 342 347
34. J.A. Ezekowitz, and F.A. McAlister Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials Eur Heart J 30 2009 469 477
35. A. Boccanelli, G.F. Mureddu, G. Cacciatore, F. Clemenza, L.A. Di, and A. Gavazzi Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results Eur J Heart Fail 11 2009 68 76
36. J.H. O'Keefe, H. Abuissa, and B. Pitt Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS Diabetes Obes Metab 10 2008 492 497
37. J.J. McMurray, J. Ostergren, K. Swedberg, C.B. Granger, P. Held, and E.L. Michelson Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771
38. A.L. Taylor, S. Ziesche, C. Yancy, P. Carson, R. D'Agostino Jr., and K. Ferdinand Combination of isosorbide dinitrate and hydralazine in blacks with heart failure N Engl J Med 351 2004 2049 2057
39. J.K. Ghali, S.W. Tam, M.L. Sabolinski, A.L. Taylor, J. Lindenfeld, and J.N. Cohn Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial J Card Fail 14 2008 718 723
40. C.O. Phillips, A. Kashani, D.K. Ko, G. Francis, and H.M. Krumholz Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials Arch Intern Med 167 2007 1930 1936
41. J.N. Cohn, and G. Tognoni Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
42. M.H. Weinberger, B. Roniker, S.L. Krause, and R.J. Weiss Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension Am J Hypertens 15 2002 709 716
43. M.H. Davidson Controversy surrounding the safety of cerivastatin Expert Opin Drug Saf 1 2002 207 212
44. L.L. Lipscombe, T. Gomes, L.E. Levesque, J.E. Hux, D.N. Juurlink, and D.A. Alter Thiazolidinediones and cardiovascular outcomes in older patients with diabetes JAMA 298 2007 2634 2643
45. S. Rinfret, M. Abrahamowicz, J. Tu, K. Humphries, M.J. Eisenberg, and H. Richard A population-based analysis of the class effect of beta-blockers after myocardial infarction Am Heart J 153 2007 224 230
46. http://www.pharmacychecker.com/strength.asp?drugid=19309. Accessed March 20, 2011.
47. http://i.walmartimages.com/i/if/hmp/fusion/customer-list.pdf. Accessed March 20, 2011.
48. M. Hayashi, T. Tsutamoto, A. Wada, T. Tsutsui, C. Ishii, and K. Ohno Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction Circulation 107 2003 2559 2565
49. N.M. Albert, C.W. Yancy, L. Liang, X. Zhao, A.F. Hernandez, and E.D. Peterson Use of aldosterone antagonists in heart failure JAMA 302 2009 1658 1665
50. L.H. Cavallari, V.L. Groo, M.A. Viana, Y. Dai, S.R. Patel, and T.D. Stamos Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure Pharmacotherapy 30 2010 1 9
51. L. Wei, A.D. Struthers, T. Fahey, A.D. Watson, and T.M. MacDonald Spironolactone use and renal toxicity: population based longitudinal analysis BMJ 340 2010 c1768
52. D.N. Juurlink, M.M. Mamdani, D.S. Lee, A. Kopp, P.C. Austin, and A. Laupacis Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 2004 543 551
53. W. Sligl, F.A. McAlister, J. Ezekowitz, and P.W. Armstrong Usefulness of spironolactone in a specialized heart failure clinic Am J Cardiol 94 2004 443 447
54. G.D.Searle LLC, division of Pfizer Inc. Inspra (eplerenone) package insert. 2008.
55. C.S. Cook, L.M. Berry, and E. Burton Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data Xenobiotica 34 2004 215 228
56. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine http://medicine iupui edu/clinpharm/ddis/ table asp. Accessed January 23, 2012.
57. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc. http://cp gm com. Accessed March 17, 2011.
58. M. Hidaka, K. Fujita, T. Ogikubo, K. Yamasaki, T. Iwakiri, and M. Okumura Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity Drug Metab Dispos 32 2004 581 583
59. R.B. Kim Drugs as P-glycoprotein substrates, inhibitors, and inducers Drug Metab Rev 34 2002 47 54
60. S.M. Rodin, and B.F. Johnson Pharmacokinetic interactions with digoxin Clin Pharmacokinet 15 1988 227 244
61. F. Bursi, S.A. Weston, M.M. Redfield, S.J. Jacobsen, S. Pakhomov, and V.T. Nkomo Systolic and diastolic heart failure in the community JAMA 296 2006 2209 2216
62. T.E. Owan, D.O. Hodge, R.M. Herges, S.J. Jacobsen, V.L. Roger, and M.M. Redfield Trends in prevalence and outcome of heart failure with preserved ejection fraction N Engl J Med 355 2006 251 259
63. G. Gerstenblith, J. Frederiksen, F.C. Yin, N.J. Fortuin, E.G. Lakatta, and M.L. Weisfeldt Echocardiographic assessment of a normal adult aging population Circulation 56 1977 273 278
64. K.K. Gaddam, E. Pimenta, S. Husain, and D.A. Calhoun Aldosterone and cardiovascular disease Curr Probl Cardiol 34 2009 51 84
65. A. Hameedi, and H.L. Chadow The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure Curr Hypertens Rep 2 2000 378 383
66. G.J. Mak, M.T. Ledwidge, C.J. Watson, D.M. Phelan, I.R. Dawkins, and N.F. Murphy Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone J Am Coll Cardiol 54 2009 1674 1682
67. National Heart Lung and Blood Institute. Aldosterone Antagonist Therapy for Adults with Heart Failure and Preserved Systolic Function (TOPCAT), NCT00094302. http://www.clinicaltrials.gov. 10-6-2009. 3-1-2011. Accessed March 1, 2011.
68. G.H. Bardy, K.L. Lee, D.B. Mark, J.E. Poole, D.L. Packer, and R. Boineau Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med 352 2005 225 237
69. M.R. Bristow, L.A. Saxon, J. Boehmer, S. Krueger, D.A. Kass, and M.T. De Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure N Engl J Med 350 2004 2140 2150
70. A.J. Moss, W.J. Hall, D.S. Cannom, J.P. Daubert, S.L. Higgins, and H. Klein Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators N Engl J Med 335 1996 1933 1940
71. A.J. Moss, W. Zareba, W.J. Hall, H. Klein, D.J. Wilber, and D.S. Cannom Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction N Engl J Med 346 2002 877 883
72. S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, and J.J. McMurray Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781
73. B.M. Massie, P.E. Carson, J.J. McMurray, M. Komajda, R. McKelvie, and M.R. Zile Irbesartan in patients with heart failure and preserved ejection fraction N Engl J Med 359 2008 2456 2467
74. J.G. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, and J. Taylor The perindopril in elderly people with chronic heart failure (PEP-CHF) study Eur Heart J 27 2006 2338 2345
75. A.P. Kalogeropoulos, and R.P. Martin Visual assessment of left ventricular function in the era of high definition: the machine and the eye of the beholder J Am Soc Echocardiogr 23 2010 265 266
76. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, R.J. Adams, J.D. Berry, and T.M. Brown Heart disease and stroke statistics-2011 update: a report from the American Heart Association Circulation 123 2011 e18 e209
77. P.A. Heidenreich, J.G. Trogdon, O.A. Khavjou, J. Butler, K. Dracup, and M.D. Ezekowitz Forecasting the future of cardiovascular disease in the united states: a policy statement from the American Heart Association Circulation 123 2011 933 944
78. J.M. Gardin, R. McClelland, D. Kitzman, J.A. Lima, W. Bommer, and H.S. Klopfenstein M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study) Am J Cardiol 87 2001 1051 1057
79. G.P. Aurigemma, J.S. Gottdiener, L. Shemanski, J. Gardin, and D. Kitzman Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study J Am Coll Cardiol 37 2001 1042 1048
80. E.T. Lee, L.D. Cowan, T.K. Welty, M. Sievers, W.J. Howard, and A. Oopik All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45-74 years, 1984-1988. The Strong Heart Study Am J Epidemiol 147 1998 995 1008
81. T.A. McDonagh, C.E. Morrison, A. Lawrence, I. Ford, H. Tunstall-Pedoe, and J.J. McMurray Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population Lancet 350 1997 829 833
82. A. Mosterd, A.W. Hoes, M.C. de Bruyne, J.W. Deckers, D.T. Linker, and A. Hofman Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study Eur Heart J 20 1999 447 455
83. M.M. Redfield, S.J. Jacobsen, J.C. Burnett Jr., D.W. Mahoney, K.R. Bailey, and R.J. Rodeheffer Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic JAMA 289 2003 194 202
84. P. Jong, S. Yusuf, M.F. Rousseau, S.A. Ahn, and S.I. Bangdiwala Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study Lancet 361 2003 1843 1848
85. K.A. Ammar, S.J. Jacobsen, D.W. Mahoney, J.A. Kors, M.M. Redfield, and J.C. Burnett Jr. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community Circulation 115 2007 1563 1570
86. J. Butler, P.G. Arbogast, J. Daugherty, M.K. Jain, W.A. Ray, and M.R. Griffin Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge J Am Coll Cardiol 43 2004 2036 2043
87. J. Butler, J.B. Young, W.T. Abraham, R.C. Bourge, K.F. Adams Jr., and R. Clare Beta-blocker use and outcomes among hospitalized heart failure patients J Am Coll Cardiol 47 2006 2462 2469
88. W.A. Gattis, C.M. O'Connor, J.D. Leimberger, G.M. Felker, K.F. Adams, and M. Gheorghiade Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure Am J Cardiol 91 2003 169 174
89. W.A. Gattis, C.M. O'Connor, D.S. Gallup, V. Hasselblad, and M. Gheorghiade Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial J Am Coll Cardiol 43 2004 1534 1541
90. J. Butler, D.E. Forman, W.T. Abraham, S.S. Gottlieb, E. Loh, and B.M. Massie Relationship between heart failure treatment and development of worsening renal function among hospitalized patients Am Heart J 147 2004 331 338
91. D.E. Forman, J. Butler, Y. Wang, W.T. Abraham, C.M. O'Connor, and S.S. Gottlieb Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure J Am Coll Cardiol 43 2004 61 67
92. L.R. Punnoose, M.M. Givertz, E.F. Lewis, P. Pratibhu, L.W. Stevenson, and A.S. Desai Heart failure with recovered ejection fraction: a distinct clinical entity J Card Fail 17 2011 527 532
93. D.M. McNamara, R.C. Starling, L.T. Cooper, J.P. Boehmer, P.J. Mather, and K.M. Janosko Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study J Am Coll Cardiol 58 2011 1112 1118
94. F. Zannad, J.J. McMurray, H. Drexler, H. Krum, D.J. van Veldhuisen, and K. Swedberg Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF) Eur J Heart Fail 12 2010 617 622
95. T. Antoniou, T. Gomes, M.M. Mamdani, Z. Yao, C. Hellings, and A.X. Garg Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study BMJ 343 2011 d5228